Literature DB >> 34224372

The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.

Monal Patel1, Yinu Wang2, Elizabeth T Bartom3,4, Rohin Dhir5, Kenneth P Nephew6, Daniela Matei2,7, Andrea E Murmann1, Ernst Lengyel5, Marcus E Peter8,3,7.   

Abstract

Ovarian cancer remains one of the deadliest gynecologic malignancies affecting women, and development of resistance to platinum remains a major barrier to achieving a cure. Multiple mechanisms have been identified to confer platinum resistance. Numerous miRNAs have been linked to platinum sensitivity and resistance in ovarian cancer. miRNA activity occurs mainly when the guide strand of the miRNA, with its seed sequence at position 2-7/8, is loaded into the RNA-induced silencing complex (RISC) and targets complementary short seed matches in the 3' untranslated region of mRNAs. Toxic 6mer seeds, which target genes critical for cancer cell survival, have been found in tumor-suppressive miRNAs. Many siRNAs and short hairpin RNAs (shRNA) can also kill cancer cells via toxic seeds, the most toxic of which carry G-rich 6mer seed sequences. We showed here that treatment of ovarian cancer cells with platinum led to increased RISC-bound miRNAs carrying toxic 6mer seeds and decreased miRNAs with nontoxic seeds. Platinum-tolerant cells did not exhibit this toxicity shift but retained sensitivity to cell death mediated by siRNAs carrying toxic 6mer seeds. Analysis of RISC-bound miRNAs in tumors from patients with ovarian cancer revealed that the ratio between miRNAs with toxic versus nontoxic seeds was predictive of treatment outcome. Application of the 6mer seed toxicity concept to cancer relevant miRNAs provides a new framework for understanding and predicting cancer therapy responses. SIGNIFICANCE: These findings demonstrate that the balance of miRNAs that carry toxic and nontoxic 6mer seeds contributes to platinum resistance in ovarian cancer. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34224372      PMCID: PMC8338879          DOI: 10.1158/0008-5472.CAN-21-0953

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  An estimate of the total number of true human miRNAs.

Authors:  Julia Alles; Tobias Fehlmann; Ulrike Fischer; Christina Backes; Valentina Galata; Marie Minet; Martin Hart; Masood Abu-Halima; Friedrich A Grässer; Hans-Peter Lenhof; Andreas Keller; Eckart Meese
Journal:  Nucleic Acids Res       Date:  2019-04-23       Impact factor: 16.971

2.  Characterization of microRNAs involved in embryonic stem cell states.

Authors:  Bradford Stadler; Irena Ivanovska; Kshama Mehta; Sunny Song; Angelique Nelson; Yunbing Tan; Julie Mathieu; Christopher Darby; C Anthony Blau; Carol Ware; Garrick Peters; Daniel G Miller; Lanlan Shen; Michele A Cleary; Hannele Ruohola-Baker
Journal:  Stem Cells Dev       Date:  2010-07       Impact factor: 3.272

Review 3.  Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Authors:  Roshan Agarwal; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

4.  GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay.

Authors:  Ana Eulalio; Eric Huntzinger; Elisa Izaurralde
Journal:  Nat Struct Mol Biol       Date:  2008-03-16       Impact factor: 15.369

Review 5.  Molecular mechanisms of drug resistance in ovarian cancer.

Authors:  Leyla Norouzi-Barough; Mohammad Reza Sarookhani; Mohammadreza Sharifi; Sahar Moghbelinejad; Saranaz Jangjoo; Rasoul Salehi
Journal:  J Cell Physiol       Date:  2018-01-04       Impact factor: 6.384

6.  Structure of the guide-strand-containing argonaute silencing complex.

Authors:  Yanli Wang; Gang Sheng; Stefan Juranek; Thomas Tuschl; Dinshaw J Patel
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

7.  Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.

Authors:  Jaine K Blayney; Timothy Davison; Nuala McCabe; Steven Walker; Karen Keating; Thomas Delaney; Caroline Greenan; Alistair R Williams; W Glenn McCluggage; Amanda Capes-Davis; D Paul Harkin; Charlie Gourley; Richard D Kennedy
Journal:  Nucleic Acids Res       Date:  2016-06-28       Impact factor: 16.971

8.  MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.

Authors:  Ningwei Li; Lingyun Yang; Hongjing Wang; Tao Yi; Xibiao Jia; Cen Chen; Pan Xu
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

9.  Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells.

Authors:  Joshua M Corbin; Constantin Georgescu; Jonathan D Wren; Chao Xu; Adam S Asch; Maria J Ruiz-Echevarría
Journal:  Mol Ther Nucleic Acids       Date:  2021-03-05       Impact factor: 8.886

10.  Induction of DISE in ovarian cancer cells in vivo.

Authors:  Andrea E Murmann; Kaylin M McMahon; Ashley Haluck-Kangas; Nandini Ravindran; Monal Patel; Calvin Y Law; Sonia Brockway; Jian-Jun Wei; C Shad Thaxton; Marcus E Peter
Journal:  Oncotarget       Date:  2017-10-04
View more
  3 in total

Review 1.  DISE/6mer seed toxicity-a powerful anti-cancer mechanism with implications for other diseases.

Authors:  Ashley Haluck-Kangas; Monal Patel; Bidur Paudel; Aparajitha Vaidyanathan; Andrea E Murmann; Marcus E Peter
Journal:  J Exp Clin Cancer Res       Date:  2021-12-10

2.  SPOROS: A pipeline to analyze DISE/6mer seed toxicity.

Authors:  Elizabeth T Bartom; Masha Kocherginsky; Bidur Paudel; Aparajitha Vaidyanathan; Ashley Haluck-Kangas; Monal Patel; Kaitlyn L O'Shea; Andrea E Murmann; Marcus E Peter
Journal:  PLoS Comput Biol       Date:  2022-03-31       Impact factor: 4.779

3.  Identification of the toxic 6mer seed consensus for human cancer cells.

Authors:  Monal Patel; Elizabeth T Bartom; Bidur Paudel; Masha Kocherginsky; Kaitlyn L O'Shea; Andrea E Murmann; Marcus E Peter
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.